June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
The impact of the OrCam device on the quality of life in patients with inherited retinal dystrophies
Author Affiliations & Notes
  • Xuan-Thanh-An Nguyen
    Department of Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Jan Koopman
    Royal Dutch Visio, Center of expertise for visually impaired people, Amsterdam, Netherlands
  • Maria M. van Genderen
    Department of Ophthalmology, University Medical Center Utrecht, Netherlands
    Bartimeus, Diagnostic Center for complex visual disorders, Zeist, Netherlands
  • Henk Stam
    Bartimeus, Diagnostic Center for complex visual disorders, Zeist, Netherlands
  • Camiel J F Boon
    Department of Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
    Department of Ophthalmology, Amsterdam UMC, Academic Medical Center, Amsterdam, Netherlands
  • Footnotes
    Commercial Relationships   Xuan-Thanh-An Nguyen, None; Jan Koopman, None; Maria van Genderen, None; Henk Stam, None; Camiel Boon, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3606. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xuan-Thanh-An Nguyen, Jan Koopman, Maria M. van Genderen, Henk Stam, Camiel J F Boon; The impact of the OrCam device on the quality of life in patients with inherited retinal dystrophies. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3606.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of this study was to investigate the impact of the OrCam MyEye device on the quality of life in patients with inherited retinal dystrophies (IRD). The OrCam is a portable visual aid device, which is mounted to the frame of eyeglasses, that translates visual information to auditive feedback (e.g. text-to-speech, barcode and facial recognition).

Methods : This prospective, observational study included 20 patients with low vision (BCVA< 20/200 Snellen) due to retinitis pigmentosa (n = 9; 45%) or cone-rod dystrophies (n = 11; 55%). After receiving extensive instructions on the OrCam, patients tested the OrCam for ± 5 weeks. Interviews were conducted before and after OrCam usage, which included the Dutch version of the NEI-VFQ-25, a modified version of the Dutch Activity Inventory (D-AI), and the OrCam Function Questionnaire (OFQ).

Results : At final visit, a significant improvement in the ‘near vision’ subscale of the NEI-VFQ-25 was observed (p < 0.001), which did not differ between retinitis pigmentosa or cone-rod dystrophy patients (p = 0.446). No significant changes were seen in the priority scores of the different goals of the D-AI. The OFQ showed an overall improvement in performing vision-related tasks (p < 0.001), although patients reported more difficulty in using the OrCam during lower light situations.

Conclusions : The OrCam MyEye is a promising low vision aid for patients with a IRD that have rehabilitation needs in reading domains. Other functionalities of the OrCam, in the current state, were reported to be less effective, suggesting that these are areas for potential improvement.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×